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Many viruses that assemble their capsids in the eukaryotic cytoplasm require a threshold concentration of capsid protein to achieve capsid
assembly. Strategies for achieving this include maintaining high levels of capsid protein synthesis and targeting to specific sites to raise the
effective concentration of capsid polypeptides. To understand how different viruses achieve the threshold capsid protein concentration
required for assembly, we used cell-free systems to compare capsid assembly of hepatitis B virus (HBV) and three primate lentiviruses.
Capsid formation of these diverse viruses in a common eukaryotic extract was dependent on capsid protein concentration. HBV capsid
assembly was also dependent on the presence of intact membrane surfaces. Surprisingly, not all of the primate lentiviral capsid proteins
examined required myristoylation and intact membranes for assembly, even though all contain a myristoylation signal. These findings reveal
significant diversity in how different capsid proteins assemble in the same cellular extract.
D 2004 Elsevier Inc. All rights reserved.
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Many different enveloped viruses, including those in the
Hepadnaviridae, Retroviridae, and Flaviviridae families,
assemble spherical capsids (the protein shells that house
the viral genome) in the cytoplasm, or at the cytoplasmic
face of a membrane. While these viruses have very different
mechanisms of replication, they all face similar problems
during the assembly process, which involves multimeriza-
tion of capsid proteins in the crowded eukaryotic cytoplasm.
Because the cytoplasm is an unfavorable environment for
homotypic interactions (reviewed in Ellis, 2001), viruses are
likely to have developed mechanisms for promoting
assembly of newly synthesized capsid proteins (reviewed0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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different capsid proteins assemble in the same cellular
environment would be useful for identifying whether viruses
use different strategies for assembly in eukaryotic cells.
Cell-free systems that support viral capsid assembly are
ideal for studying mechanisms of virus assembly in a
cellular environment. These systems utilize a cellular extract
to assemble capsids from newly synthesized capsid proteins,
and thereby recapitulate the process of assembly that occurs
in vivo. Furthermore, they are more amenable to exper-
imental manipulation than intact cells (reviewed in Lingappa
and Lingappa, in press). Previously, we have established
cell-free capsid assembly systems for studying a hepadna-
virus, hepatitis B virus (HBV; Lingappa et al., 1994), and a
flavivirus, hepatitis C virus (HCV; Klein et al., 2004,
submitted for publication). In addition, we have developed
cell-free assembly systems for three related primate lentivi-
ruses: human immunodeficiency virus type 1 isolate SF2
(HIV-1 SF2; Lingappa et al., 1997; Zimmerman et al.,05) 114–123
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clone 304 (HIV-2 304; Dooher and Lingappa, 2004a, 2004b;
Dooher et al., 2004), and the Sabeus strain of simian
immunodeficiency virus from African green monkeys
(SIVagm Sab; Dooher and Lingappa, 2004a, 2004b). Cell-
free capsid assembly systems have also been developed for
Gag from the HIV-1 isolate HXB2 (Spearman and Ratner,
1996), and Mason-Pfizer monkey virus (M-PMV), a D-type
retrovirus (Sakalian and Hunter, 1999; Sakalian et al., 1996).
During HBV assembly, the newly-synthesized structural
protein core undergoes dimerization (Seifer et al., 1993;
Zhou et al., 1992) followed by multimerization to form a
single capsid composed of either 180 or 240 capsid proteins.
HBV capsid assembly occurs in the cytoplasm and results in
encapsidation of the HBV genome and polymerase as well
as the cellular chaperone Hsp90 (Hu and Seeger, 1996; Hu
et al., 1997). HBV capsid formation is followed by reverse
transcription of the RNA genome within the capsid, budding
of the capsids into the endoplasmic reticulum (ER), and
release via the secretory pathway (reviewed in Ganem and
Prince, 2004; Nassal, 1999). In contrast, a single primate
lentivirus capsid is composed of ~5000 copies of the viral
structural protein Gag (Briggs et al., 2004). Gag polypep-
tides undergo myristoylation, target to the cytoplasmic face
of the plasma membrane or the multivesicular body, and
multimerize at the membrane to form a single immature
capsid. During assembly, the HIV genome, other viral
proteins, and specific cellular proteins are packaged into the
assembling capsid. Release occurs by budding from the
plasma membrane, with subsequent maturation of the viral
capsid occurring through the action of the viral protease
(reviewed in Adamson and Jones, 2004; Freed, 1998). The
Gag proteins of HIV-1, HIV-2, and SIVagm Sab belong to
different primate lentivirus subgroups (Hahn et al., 2000),
share ~50% amino acid identity, and are thought to assemble
in a similar manner (Dooher and Lingappa, 2004b).
Assembly of the capsid proteins of HBV (core protein)
and primate lentiviruses (Gag protein) can occur in cells in
the absence of other viral proteins (reviewed in Adamson
and Jones, 2004; Freed, 1998; Nassal, 1996) and can be
faithfully recapitulated in cell-free systems (Dooher and
Lingappa, 2004a, 2004b; Lingappa et al., 1994, 1997).
A common problem faced by many viruses during
assembly involves achieving the threshold level of capsid
protein that is needed for their multimerization. Multiple
mechanisms may exist for achieving these levels in the
eukaryotic cytoplasm, and some viruses may use more than
one mechanism to ensure that a sufficient concentration is
reached. One mechanism for meeting the threshold concen-
tration involves synthesis of high levels of capsid protein in
the cytoplasm. For HBV, the dependence of assembly on
capsid protein concentration has been demonstrated both in
vitro (Ceres and Zlotnick, 2002) and in the eukaryotic
cytoplasm (Seifer et al., 1993). A second general mecha-
nism involves targeting to raise the concentration of capsid
protein at the site of assembly. Targeting to membranes iscritical for directing capsid assembly to the site of release,
but, in addition, membrane targeting is thought to raise local
concentrations of capsid proteins, further increasing capsid
protein concentration (Ono and Freed, 2001). Such mem-
brane targeting can be mediated by specific signals. In the
case of primate lentiviral Gag proteins, targeting to
membrane surfaces is governed by a N-terminal myristate
(Bryant and Ratner, 1990; Gheysen et al., 1989; Gottlinger
et al., 1989; Lee and Linial, 1994; Morikawa et al., 1996;
Pal et al., 1990; Perez-Caballero et al., 2004) as well as
adjacent basic residues (Freed et al., 1994; Ono and Freed,
1999; Ono et al., 1997; Spearman et al., 1994; Yuan et al.,
1993; Zhou et al., 1994). Nonspecific interactions of capsid
proteins with RNA constitute a third mechanism for
promoting multimerization. While it is thought that RNAs
are used during assembly as a scaffold (Cimarelli et al.,
2000; reviewed in Berkowitz et al., 1996), they may also act
to raise the local concentration of capsid proteins during
assembly (reviewed in Adamson and Jones, 2004). The
effect of RNA has been described using purified recombi-
nant retrovirus capsid protein systems in which addition of
nonspecific RNA or oligonucleotides is found to promote
multimerization (e.g., Campbell and Rein, 1999; Campbell
and Vogt, 1995).
Here, we compare strategies used by different viruses for
concentrating capsid proteins during assembly in a cyto-
plasmic environment. To do this, we took advantage of cell-
free assembly systems because they provide a uniform
cellular context that can be manipulated experimentally. We
compared the extent to which cell-free assembly of different
viral capsids (HBV; HIV-1 SF2; HIV-2 304; and SIVagm
Sab) is dependent upon levels of capsid protein synthesis,
the presence of intact membrane surfaces, and myristoyla-
tion. Our findings reveal that different capsid proteins,
including those with related sequences, use unexpectedly
diverse mechanisms for assembly within the same cyto-
plasmic extract.Results
Cell-free systems produce similar amounts of different viral
capsid proteins
As a first step in testing the hypothesis that concentration
of capsid protein is a critical determinant of assembly, we
quantified the amount of capsid protein synthesized in cell-
free capsid assembly systems that contain wheat germ
extracts as a source of cellular factors. We have shown
previously that the amount of HCV core protein produced in
cell-free HCV assembly reactions is ~30 ng per Al (Klein et
al., 2004), which is equivalent to ~1.5 AM core protein.
However, since the amount of capsid protein translated in
the cell-free system may not be the same for capsid proteins
of other viruses, we examined capsid protein production in
two other cell-free capsid assembly systems (Fig. 1).
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quantities of purified, recombinant HBV core and HIV-1
SF2 Gag protein. Aliquots of unlabeled cell-free assembly
reactions programmed with transcript for the 21-kDa HBV
core protein or the 55-kDa HIV-1 SF2 Gag protein wereFig. 1. Amount of capsid protein synthesis in HBV core and HIV-1 SF2
Gag cell-free assembly systems. (A) Purified HBV core protein (25, 50, 75,
and 100 ng) was immunoblotted with anti-HBV core antibody to obtain a
standard curve, shown as an immunoblot (HBV core standard). Different
amounts (2.5, 5, and 10 Al) of an HBV core cell-free assembly reaction
programmed with unlabeled amino acids (CFS HBV core) were analyzed in
parallel with HBV core standards. Band density of HBV core standards was
quantified and graphed (solid line). Band density of HBV core in cell-free
reactions was also quantified and interpolated on the standard curve (best-fit
line) to calculate the amount of HBV core present in 1 Al of cell-free
reaction. Dotted line and solid circle show interpolation of 5 Al HBV core
cell-free reaction. Average amount of HBV core present in a cell-free
translation (10 ng HBV core per Al cell-free reaction) was obtained by
averaging the results obtained by interpolating the 2.5, 5, and 10 Al cell-free
reactions. (B) A best-fit line was obtained as described above except that
different quantities of purified HIV-1 Gag standard and different amounts of
an HIV-1 Gag cell-free reaction (CFS HIV-1 Gag) were used in the
immunoblot. A cell-free reaction programmed with mock transcript (CFS
mock) was included as a negative control. Interpolation is shown for 2.5 Al
HIV-1 Gag SF2 cell-free reaction.immunoblotted in parallel with standards. The amount of
capsid protein in each cell-free sample was determined by
interpolating different quantities of cell-free assembly
reactions on the appropriate standard curve. In three
separate determinations, the average amount of HBV core
produced was ~10 ng per Al of cell-free assembly reaction
(Fig. 1A), which is equivalent to ~0.5 AM. Cell-free
reactions programmed with HIV-1 SF2 Gag transcript
produced on average ~30 ng Gag per Al of cell-free
assembly reaction (Fig. 1B), which is also ~0.5 AM. Thus,
comparable amounts of capsid protein (10–30 ng, or 0.5–1.5
AM) are produced when cell-free assembly systems con-
taining wheat germ extracts are programmed with transcript
encoding capsid proteins of HBV, HIV-1 SF2, or HCV.
Cell-free assembly of HBV, HIV-1 SF2 and HIV-2 304
capsids is dependent on capsid protein concentration
In cell-free assembly reactions, the amount of capsid
protein produced is dependent on the amount of mRNA
transcript added to the translation reaction. Previously, we
have used reactions programmed with diluted transcript as a
means of accumulating unassembled HBV core polypep-
tides (Lingappa et al., 1994). These experiments suggested
that HBV capsid assembly is sensitive to core protein
concentration in the cell-free system, just as it is in cells
(Seifer et al., 1993), although the details of the cell-free
concentration dependence were not examined.
To date, it remains unclear whether assembly of primate
lentivirus capsids is similarly dependent on capsid protein
concentration. To examine the effect of decreasing capsid
protein synthesis on assembly of HBV, HIV-1 SF2, and
HIV-2 304 capsids, we programmed cell-free reactions with
either the standard amount of capsid transcript (100%) or
with diluted transcript (Fig. 2). Dilution of transcript was
performed by mixing transcript encoding capsid protein
with either mock transcript (which is programmed with
water rather than a cDNA) or with transcript encoding a
cellular protein (human HP68 or globin). The total amount
of radiolabeled core protein translated in each reaction was
determined by SDS-PAGE followed by autoradiography
and densitometry. To assess amount of capsid assembly,
cell-free assembly reactions were analyzed by velocity
sedimentation gradients that separate completely assembled
capsids from unassembled capsid protein and assembly
intermediates, as previously described (Lingappa et al.,
1994, 1997). In the case of HBV, nearly 40% of HBV core
protein assembled into ~100S capsids under optimal
conditions (designated maximal assembly). Dilution of
HBV core transcript using mock transcript resulted in a
decrease in HBV core protein synthesis as expected (Fig.
2A, dotted line), as well as a corresponding decrease in
HBV core assembly (Fig. 2A, bar graph). Similar results
were obtained when cell-free reactions were programmed
with diluted HIV-1 SF2 Gag transcript (Fig. 2B) or HIV-2
304 Gag transcript (Fig. 2C). For example, a reduction in
Fig. 3. Primate lentiviruses differ in their requirement for an intact
membrane surface during cell-free assembly. Cell-free assembly reactions
were programmed with standard amounts of HBV, HIV-1 SF2, or HIV-2
304 transcript. At the start of the cell-free reaction, the non-ionic detergent
Nikkol was added to the following final concentrations: 0.0001% Nikkol
(dark grey); 0.1% Nikkol (medium grey); 0.2% Nikkol (light grey). Total
volume for all cell-free reactions was kept constant. Shown below graph are
autoradiographs of equivalent aliquots of total cell-free reactions. The
experiments were performed three independent times for each viral capsid
protein and data shown are from one representative experiment.
Fig. 2. Cell-free capsid assembly of HBV, HIV-1 SF2, and HIV-2 304 is
dependent on capsid protein concentration. (A) HBV core cell-free
reactions were programmed with either the standard amount of HBV core
transcript (100%), or with HBV core transcript diluted with mock transcript
as indicated. The amount of HBV capsid assembly (left axis, bar graph) and
the amount of HBV core synthesis (right axis, dotted line) were quantified
and graphed for each % transcript. Synthesis and assembly were normalized
to amount obtained when 100% transcript was used (% of maximum). (B
and C) HIV-1 SF2 Gag (B) or HIV-2 304 Gag (C) cell-free reactions were
programmed with either the standard amount of HIV-1 transcript (100%) or
with HIV-1 transcript diluted as indicated with transcript encoding a cellular
protein (either HuHP68, shown; or globin, data not shown). Quantitation
and graphing was performed as in A above. The experiment was performed
three independent times for each viral capsid protein and data shown are
from one representative experiment.
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resulted in a corresponding decrease in HIV-1 SF2 Gag
assembly to 62% of maximal assembly (Fig. 2B).
Primate lentiviruses differ in sensitivity of capsid assembly
to membrane disruption
The wheat germ extract used in our assembly systems is
a source of cellular factors for translation and assembly and
also contains some small membranous organelles, such as
vesicles. Sufficient concentrations of non-ionic detergents,such as Nikkol, can disrupt such membranes without
affecting enzymatic reactions (Walter and Blobel, 1980).
Previously, we found that HCV capsid assembly in a cell-
free system was not affected when Nikkol was added at the
start of the cell-free reaction at concentrations (0.1% and
0.2%) that would be expected to disrupt membrane integrity
but have no effect on protein synthesis (Klein et al., 2004).
These data suggested that HCV capsids can assemble into
capsids in the absence of intact membrane surfaces. In
contrast, previous data suggested that intact membrane
surfaces are critical for assembly of HIV-1 SF2 Gag, since
treatment of HIV assembly reactions with Nikkol at 0.1% or
higher at the start of the cell-free reaction abolished HIV-1
SF2 capsid assembly (Lingappa et al., 1997; and see Fig. 3).
Furthermore, when Nikkol was added at the end of the
assembly reaction, no effect on HIV-1 SF2 capsids was
seen, indicating that the assembly process rather than the
integrity of completely assembled immature capsids is
detergent sensitive (Lingappa et al., 1997).
The striking difference in detergent sensitivity of cell-free
HCV and HIV-1 SF2 capsid assembly led us to examine
whether cell-free assembly of other viral capsids is depend-
ent on intact membranes. Nikkol treatment had no signifi-
cant effect on the amount of translation of any capsid
protein examined (Fig. 3, autoradiographs), and Nikkol at
0.0001%, had no effect on assembly of any capsid examined
(Fig. 3). Nikkol added at a concentration of 0.1% or greater
abolished cell-free assembly of HBV capsids, as was the
case for HIV-1 SF2. In contrast, 0.1% and even 0.2% Nikkol
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graph). The finding that HIV-2 304 immature capsid
assembly was unaffected by concentrations of Nikkol that
abolished HIV-1 SF2 capsid assembly in an identical extract
suggests that HIV-2 304 immature capsid assembly in the
cell-free system does not require intact membranes. Fur-
thermore, these data suggest that related primate lentiviruses
vary in the extent to which they require an intact membrane
surface for capsid assembly. Of note, these two primate
lentiviral Gag proteins share approximately 60% amino acid
similarity and 50% identity (Dooher and Lingappa, 2004b).
HIV-2 304 capsid assembly does not require myristoylation
of Gag, in contrast to other primate lentiviruses
All lentiviral Gag proteins examined here contain an N-
terminal myristoylation signal (Fig. 4A), while HBV core
does not. Myristoylation occurs at the consensus sequence,
Met-Gly-X-X-X-Ser/Thr, and is catalyzed by the enzyme N-
myristoyl transferase (Towler et al., 1988), using myristoyl
coenzyme A (MCoA) as a fatty acid donor. Wheat germ
extract contains N-myristoyl transferase (Heuckeroth et al.,
1988), however, during processing of wheat germ, smallFig. 4. Some but not all primate lentiviruses require Gag myristoylation for imma
amino acids for the three primate lentiviral Gag proteins studied here shows that a
by a region high in basic charge. White shading indicates identity; grey indi
substitution. (B) Cell-free reactions were programmed with the indicated transcr
Reactions were analyzed by velocity sedimentation and the amount of assembly in
protein). Shown below the graph are autoradiographs of equivalent aliquots of eac
lanes are from the same film except for SIVagm Sab, which is synthesized at lowe
separate experiment containing an HIV-1 control. The experiment was performed t
are shown here.molecules such as MCoA are lost during gel filtration. For
this reason, MCoA must be added exogenously to cell-free
capsid assembly systems for sufficient myristoylation to
occur. Several lines of evidence indicate that myristoylation
of HIV-1 Gag is important for HIV-1 Gag multimerization in
cells, in addition to Gag targeting and release. For example,
full-length Gag proteins containing a GDA mutation
(2GDA) that abolishes myristoylation (Bryant and Ratner,
1990; Gottlinger et al., 1989) fail to produce capsid-like
structures in primate cells, as indicated by electron micro-
scopic analyses (Spearman et al., 1994). Consistent with this
observation, we previously found that myristoylation of
HIV-1 SF2 Gag is required for efficient assembly of
immature HIV-1 SF2 capsids in the cell-free system
(Lingappa et al., 1997).
For this reason and because of the differences observed
in membrane dependence, we examined whether myristoy-
lation is critical for assembly of SIVagm Sab and HIV-2 304
immature capsids, as is the case for HIV-1 SF2 capsid
assembly. HIV-1 SF2 Gag did not assemble to a significant
extent in the absence of MCoA (Fig. 4B graph, lanes 1 and
2), as previously reported (Lingappa et al., 1997). Similarly,
SIVagm Sab Gag did not assemble efficiently into ~750Sture capsid assembly in the cell-free system. (A) Alignment of N-terminal
ll contain the myristoylation consensus: Met-Gly-X-X-X-Ser/Thr, followed
cates conservative substitution; black shading indicates non-conservative
ipts either in the presence (+) or absence () of myristoyl CoA (MCoA).
to completed capsids was determined and quantitated (as % of total capsid
h translation reaction performed in the presence and absence of MCoA. All
r levels and requires a longer exposure, and HBV, which was analyzed in a
hree independent times for each viral capsid protein and representative data
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added MCoA (Fig. 4B graph, lanes 5 and 6). Surprisingly,
HIV-2 304 Gag assembled into ~750S immature capsids to a
similar extent in the presence or absence of MCoA (Fig. 4B
graph, lanes 7 and 8). To confirm these results, we
engineered a 2GDA mutation in HIV-2 304 Gag to abolish
its myristoylation consensus. An analogous mutation in
HIV-1 SF2 Gag has been shown to abolish cell-free capsid
assembly (Lingappa et al., 1997; and Fig. 4B graph, lanes 3
and 4). In contrast to results obtained with HIV-1 SF2 GDA
Gag, cell-free reactions programmed with HIV-2 304 GDA
Gag assembled efficiently in the presence or absence of
MCoA (Fig. 4B graph, lanes 9 and 10, compare to lanes 3
and 4). These data suggest that, like HIV-1, SIVagm Sab
Gag requires myristoylation for assembly, while HIV-2 304
Gag does not. As expected, assembly of HBV core, which
does not contain a myristoylation signal, was unaffected by
addition of MCoA (Fig. 4B graph, lanes 11 and 12).
Amount of synthesis of all constructs was not altered by
addition of MCoA (Fig. 4B, autoradiograph), as expected.
To validate that the ~750S complexes made by HIV-2
304 Gag in the absence of MCoA are indeed immature
capsids, we harvested these particles following velocity
sedimentation and subjected them to equilibrium centrifu-
gation on cesium chloride, which separates particles by
density (in contrast to velocity sedimentation, which
separates particles on the basis of size and shape). Both
the ~750S complexes produced by HIV-1 SF2 Gag in the
presence of MCoA and the ~750S complexes produced by
HIV-2 304 Gag in the absence of MCoA migrated in the
same fractions on cesium gradients, peaking in fraction 5
(Fig. 5). Refractometry measurements revealed that fraction
4 corresponds to a density of 1.36 g/ml, which is the
expected density of immature primate lentivirus capsids inFig. 5. Non-myristoylated HIV-2 304 Gag forms capsids as indicated by buoyant d
in the presence of MCoA and HIV-2 304 Gag in the absence of MCoAwere subje
layered onto cesium chloride and subjected to equilibrium centrifugation. Half of e
in g/ml (dotted line with shaded triangles). The other half of each fraction was an
radiolabeled HIV-1 SF2 Gag (dark squares) and HIV-2 304 Gag (open diamonds) i
reveals a peak at 1.36 g/ml. The experiment was repeated twice and the results scesium chloride (Dooher et al., 2004; Lingappa et al., 1997).
Together, these data indicate that HIV-2 304 Gag, unlike
HIV-1 SF2 and SIVagm Sab Gag, efficiently assembles into
immature capsids of the correct size, shape, and density in
the cell-free system even in the absence of myristoylation.
Thus, cell-free capsid assembly of these three related
primate lentiviruses differs in dependence on myristoyla-
tion, even though all three contain myristoylation signals in
the N-termini that fit the canonical consensus and closely
resemble each other (Fig. 4B).Discussion
In comparing assembly of different viral capsid proteins
in a cellular extract, we have identified surprising differ-
ences in how different capsid proteins achieve threshold
capsid protein concentrations needed for assembly. Use of
cell-free systems allowed us to alter one variable, such as
concentration of capsid protein transcript, presence of intact
membranes, and presence of the cofactor for myristoylation,
while keeping other relevant variables constant. We found
that HBV capsid assembly in the cell-free system (Fig. 2A)
recapitulates the concentration dependence seen for HBV in
cells (Seifer et al., 1993). In addition, assembly of HIV-1
SF2 and HIV-2 304 capsids display a similar dependence on
capsid protein concentration (Figs. 2B and C), suggesting
that diverse viruses require threshold levels of capsid protein
synthesis. However, not all viral capsids appear to share this
characteristic. We recently demonstrated that HCV capsid
assembly in a cell-free system is relatively concentration
independent (Klein et al., 2004), despite capsid protein
levels comparable to those found in the concentration
dependent systems described here (see Fig. 1). Theseensity measurements. Cell-free reactions programmed with HIV-1 SF2 Gag
cted to velocity sedimentation. Fractions containing ~750S complexes were
ach fraction was subjected to refractometry to obtain density of each fraction
alyzed by SDS-PAGE and autoradiography. Solid lines show the amount of
n each cesium fraction plotted against the fraction number, and in both cases
hown are from one representative experiment.
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capsid assembly of different viruses within the same extract
raise the possibility that two fundamentally different
assembly mechanisms exist for viral capsids that assemble
at cytoplasmic faces of membranes. Examination in cellular
systems will be required to test this hypothesis.
While the three primate lentiviruses we studied showed a
similar dependence on the level of capsid protein synthesis,
they differed in their dependence on myristoylation and
intact membranes for the purpose of promoting capsid
assembly. Cell-free assembly of HIV-1 SF2 Gag was
dependent on intact membranes and myristoylation, while
cell-free assembly of HIV-2 304 Gag did not display a
membrane dependence or require myristoylation (Figs. 3
and 4). In intact cells, proper assembly of wild-type HIV-1
Gag appears to require myristoylation (Spearman et al.,
1994), although the exact reason for this remains unclear.
Current thinking holds that Gag-Gag interactions that occur
during multimerization cause a conformational change that
exposes the myristate at the N-terminus of Gag and leads to
membrane binding (the myristoyl switch model; e.g. Ono et
al., 2000; Paillart and Gottlinger, 1999; Perez-Caballero et
al., 2004; Sandefur et al., 2000; Spearman et al., 1994; Zhou
et al., 1994). Membrane binding is thought to raise the local
concentration of Gag at the membrane to the threshold
needed for subsequent multimerization of Gag, resulting in
capsid assembly at the appropriate site for release. There-
fore, we were surprised to find that HIV-2 304 Gag can
assemble efficiently in the absence of myristoylation or
intact membranes in the cell-free system. These data suggest
that some primate lentiviral Gag polyprotein variants may
contain sequence differences that allow them to utilize other
mechanisms for promoting assembly, while still using
myristoylation and membrane targeting in cells to ensure
virus release by budding from the plasma membrane. An
alternate assembly scheme is seen with the D-type retrovirus
Mason-Pfizer monkey virus (M-PMV), which appears to
use an 18-amino acid cytoplasmic targeting/retention signal
(CTRS) to concentrate its Gag proteins in the pericentriolar
region where assembly occurs (Choi et al., 1999; Rhee and
Hunter, 1987; Sfakianos et al., 2003). The hypothesis that
alternate concentrating mechanisms may exist for some
primate lentiviral Gag proteins will need to be tested by
examining whether HIV-2 304 assembly can occur inde-
pendently of myristoylation and membrane targeting in
intact cells.
In our study, assembly of HBV capsids was not depend-
ent on myristoylation, as expected given the lack of a
myristoylation signal in HBV core. Interestingly, assembly
of HBV capsids was detergent sensitive, implying that an
intact membrane surface is required for assembly in the cell-
free system. HBV core is known to contain a nuclear
localization signal and a nuclear export signal (Kann et al.,
1999; Mabit et al., 2001; Rabe et al., 2003), but is not
known to contain intrinsic membrane targeting signals. An
alternate form of core (precore) that gives rise to the HBV eantigen is known to contain a signal sequence that targets it
to the ER (Garcia et al., 1988), but precore is not thought to
give rise to capsid protein in vivo and was not utilized in
this study. HBV capsids are thought to assemble in the
cytoplasm and subsequently target to the ER by associating
with hepatitis B surface antigen expressed in the ER
(reviewed in Ganem and Prince, 2004; Nassal, 1996), but
our data raise the possibility that core may also have an
intrinsic membrane targeting signal that acts before or
during capsid assembly.
In conclusion, our studies of the behavior of diverse
capsid proteins during assembly in a common cellular
extract reveal significant differences in features of capsid
protein assembly. HBV and some primate lentiviral capsid
proteins (HIV-1 SF2 and SIVagm Sab) require threshold
levels of capsid protein synthesis as well as membrane
targeting to assemble efficiently in the cell-free system,
while another primate lentivirus (HIV-2 304) requires
threshold levels of capsid protein synthesis but does not
require membrane targeting for efficient capsid assembly.
This finding contrasts with previous studies showing that
HCV requires neither high levels of synthesis nor intact
membranes for assembly in the cell-free system (Klein et al.,
2004). Together, these observations suggest that viral
capsids that assemble at cytoplasmic membrane faces rely
to different extents on a variety of mechanisms for achieving
threshold concentrations of their capsid proteins.Materials and methods
Plasmids
Plasmids for cell-free expression were derived from SP64
vector (Promega) into which the 5V untranslated region
(UTR) of Xenopus laevis globin had been inserted at the
HindIII site (Melton et al., 1984). Coding regions for HBV
core (Lingappa et al., 1994), HIV-1 SF2 Gag (Lingappa et
al., 1997), HIV-2 304 Gag (Dooher and Lingappa, 2004b),
SIVagm Sab Gag (Dooher and Lingappa, 2004a), Flag-
tagged HuHP68 (Dooher and Lingappa, 2004b), and globin
(Zimmerman et al., 2002) were inserted into this vector
downstream from the UTR as described previously. Note
that the Gag constructs used encode full-length Gag (e.g.,
HIV-1 p55 Gag) but do not encode the viral protease and
therefore only produce immature capsids.
Cell-free reactions
In vitro transcription was performed with SP6 polymer-
ase using cell-free expression plasmids described above.
Cell-free translation and assembly reactions were performed
by incubating transcript (20%) with wheat germ extract
(20%), 19 unlabeled amino acids, 35S-methionine (Trans-
label, ICN), ATP, GTP, creatine phosphate, creatine kinase
and RNAse A inhibitor for 180 min at 26 8C as described
J.R. Lingappa et al. / Virology 333 (2005) 114–123 121previously (Erickson and Blobel, 1983; Lingappa et al.,
1997). Cell-free reactions in Fig. 1 were performed with 20
unlabeled amino acids and without radiolabel.
Immunoblotting
Standards in Fig. 1 included HBV core (a gift of Chiron
corporation), and purified recombinant HIV-1 SF2 p55 Gag
(catalog 5109) from the NIH AIDS Reference and Reagent
Program (donated by Chiron corporation). Immunoblotting
was performed using a-HBV core antibody (Dako) at
1:1000, or a-HIV-1 Gag p24 (Dako) at 1:600, respectively.
Anti-IgG coupled to horseradish peroxidase (HRP; Santa
Cruz) was used as a secondary antibody and enhanced
chemiluminescence (Pierce) was performed. Unlabeled cell-
free reactions were analyzed on the same immunoblot as
standards, and immunoblots were quantitated within the
linear range of detection (see below).
Gradient analysis
Ten Al of each cell-free reaction was diluted into 100 Al
NP40 buffer (10 mM TrisAc pH 7.4, 0.625% NP40, 50 mM
KAc, 100 mM NaCl, and 4 mM Mg) and analyzed by
velocity sedimentation to separate completed capsids from
assembly intermediates. The following 2 ml gradients
containing sucrose in NP40 buffer were centrifuged using
a TLS55 rotor in a Beckman Optima Max E at 4 8C. To
separate the ~100S HBV completed capsid, samples were
layered onto 10–50% sucrose gradient and centrifuged at
55,000 rpm (200,000  g) for 55 min. For separation of the
~750S completed capsid of HIV-1, HIV-2, and SIVagm Sab,
samples were layered onto step gradients containing 500 Al
each of 20%, 40%, 50%, and 75% sucrose (Figs. 2B, 3, and
4) or 400 Al each of 20%, 40%, 50%, 66%, and 75% sucrose
(Fig. 2C), and were centrifuged at 45,000 rpm (135,000 g)
for 45 min. Position of completed capsids was determined by
migration of authentic immature capsids produced in cells
(data not shown and methods described previously (Lin-
gappa et al., 1994, 1997)). Calibration of gradients to
determine S value positions has been described previously
(Lingappa et al., 1997). Two hundred Al fractions were
collected from the top and a 10 Al aliquot of each was
analyzed by SDS-PAGE and autoradiography. Percent
assembly was defined as the amount of capsid protein in
the assembled position in the gradient as a % of total capsid
protein synthesized.
Equilibrium centrifugation was performed by layering
sample (50 Al each of velocity sedimentation gradient
fractions containing ~750S completed capsids of HIV-1 or
HIV-2 304) onto cesium chloride (337 mg/ml) and
centrifuging at 50,000 rpm (166,000  g) for 22 h at 25
8C in a TLS55 rotor. Two hundred Al fractions were
collected and half of each fraction was precipitated with
trichloroacetic acid, washed with ethanol-ether, and ana-
lyzed by SDS-PAGE and autoradiography. The remainder ofeach fraction was used to obtain refractive index measure-
ments of each fraction, which were converted to density
measurements using a standard conversion table.
Quantitation
Autoradiographs and immunoblots were digitized using
an AGFA Duoscan T1200 scanner and Adobe Photoshop
6.0 software (Adobe Systems Incorporated). Mean band
densities were determined and adjusted for band size and
background using Image J software (NIH).Acknowledgments
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